George Kontopidis

List of Publications by Year in descending order

30 papers	1,170 citations	430874 18 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	1641 citing authors

#	Article	IF	Citations
1	The Ligand-binding Site of Bovine Î²-Lactoglobulin: Evidence for a Function?. Journal of Molecular Biology, 2002, 318, 1043-1055.	4.2	236
2	Statistical approaches to maximize recombinant protein expression in Escherichia coli: A general review. Protein Expression and Purification, 2014, 94, 22-32.	1.3	124
3	Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS. Structure, 2003, 11, 399-410.	3.3	115
4	Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design. Chemistry and Biology, 2006, 13, 201-211.	6.0	58
5	Quantification of the Effects of Ionic Strength, Viscosity, and Hydrophobicity on Proteinâ€“Ligand Binding Affinity. ACS Medicinal Chemistry Letters, 2014, 5, 931-936.	2.8	55
6	Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Organic and Biomolecular Chemistry, 2004, 2, 2735.	2.8	53
7	Insights into Cyclin Groove Recognition. Structure, 2003, 11, 1537-1546.	3.3	52
8	Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-ÎºB Ligand (RANKL). PLoS Computational Biology, 2017, 13, e1005372.	3.2	49
9	beta-Lactoglobulin - a three-dimensional perspective. International Journal of Food Science and Technology, 1999, 34, 409-418.	2.7	46
10	Apparent chemical composition of nine commercial or semi-commercial whey protein concentrates, isolates and fractions. International Journal of Food Science and Technology, 1999, 34, 543-556.	2.7	45
11	REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors. ChemBioChem, 2006, 7, 1909-1915.	2.6	40
12	Some physico-chemical properties of nine commercial or semi-commercial whey protein concentrates, isolates and fractions. International Journal of Food Science and Technology, 1999, 34, 587-601.	2.7	35
13	A statistical approach for optimization of RANKL overexpression in Escherichia coli: Purification and characterization of the protein. Protein Expression and Purification, 2013, 90, 9-19.	1.3	30
14	In vitro and in vivo assessment of vitamin A encapsulation in a liposomeâ€“protein delivery system. Journal of Liposome Research, 2019, 29, 142-152.	3.3	26
15	Î²-Lactoglobulin improves liposomeâ€™s encapsulation properties for vitamin E delivery. Journal of Liposome Research, 2014, 24, 74-81.	3.3	25
16	The X-ray structure of a divergent cyclophilin from the nematode parasiteBrugia malayi. FEBS Letters, 1998, 425, 361-366.	2.8	24
17	Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. Journal of Medicinal Chemistry, 2019, 62, 3886-3897.	6.4	23
18	Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly. Journal of Medicinal Chemistry, 2013, 56, 1573-1582.	6.4	19

#	Article	IF	Citations
19	Truncation and Optimisation of Peptide Inhibitors of Cyclin-Dependent Kinase 2-Cyclinâ€…A Through Structure-Guided Design. ChemMedChem, 2009, 4, 1120-1128.	3.2	17
20	A comparison of statistical approaches used for the optimization of soluble protein expression in Escherichia coli. Protein Expression and Purification, 2016, 120, 126-137.	1.3	17
21	Thermodynamic, crystallographic and computational studies of non-mammalian fatty acid binding to bovine Î²-Lactoglobulin. International Journal of Biological Macromolecules, 2018, 118, 296-303.	7.5	13
22	Synthesis and biological evaluation of potential small moleculeinhibitors of tumor necrosis factor. MedChemComm, 2015, 6, 1196-1209.	3.4	12
23	Iterative Conversion of Cyclin Binding Groove Peptides into Druglike CDK Inhibitors with Antitumor Activity. Journal of Medicinal Chemistry, 2015, 58, 433-442.	6.4	12
24	Enzymatic and structural characterization of non-peptide ligandâ€“cyclophilin complexes. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 479-485.	2.5	10
25	Catch the Kinase Conformer. Chemistry and Biology, 2006, 13, 693-694.	6.0	8
26	Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein Expression and Purification, 2015, 113, 8-16.	1.3	7
27	Ovine Î²-lactoglobulin at atomic resolution. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 1498-1503.	0.8	6
28	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-ÎºB Ligand with a Superior Therapeutic Index. Journal of Medicinal Chemistry, 2020, 63, 12043-12059.	6.4	6
29	Development and Evaluation of a Phospholipid-sterol-protein Membrane Resembling System. Food Biophysics, 2015, 10, 300-308.	3.0	4
30	Aqueous Solubility Enhancement for Bioassays of Insoluble Inhibitors and QSPR Analysis: A TNF-Î± Study. SLAS Discovery, 2018, 23, 84-93.	2.7	3